Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2025-2744

Published: 2025

Journal Articles

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

John Seymour, Andrew Aw, Vincent Ribrag, Guillaume Cartron, Arnon Kater, Ki-Seong Eom, Alan Skarbnik, Alessandra Tedeschi, Malgorzata Wach, Jing-Zhou Hou, Arpad Illes, Batul Suterwala, Jiefen Munley, Ellie John, Toshifumi Fujimori, Jennifer Brown

Blood (2025) 146 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2025-2118

Published: 2025

Journal Articles

Evaluation of PET/CT during upfront therapy as a prognosticator in follicular lymphoma patients at the University of Debrecen

Ádám Jóna, Evelin Kiss, Zsófia Simon, Arpad Illes

Blood (2025) 146 (Supplement 1): 5348.

https://doi.org/10.1182/blood-2025-5348

Published: 2025

Journal Articles

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Blood (2025) 146 (Supplement 1): 669.

https://doi.org/10.1182/blood-2025-669

Published: 2025

Journal Articles

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Blood (2025) 146 (Supplement 1): 485.

https://doi.org/10.1182/blood-2025-485

Published: 2025

Journal Articles

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Blood (2025) 146 (Supplement 1): 466.

https://doi.org/10.1182/blood-2025-466

Published: 2025

Journal Articles

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

Wojciech Jurczak, Ana Basquiera, Isabelle Fleury, Sujun Gao, Arpad Illes, Andras Masszi, Antonio Pinto, Sanne Lugthart, Omur Sevindik, Iryna Kriachok, Elizabeth Phillips, Fei Li, Chan Cheah, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Fangfang Lv

Blood (2025) 146 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2025-3570

Published: 2025

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Blood (2024) 144 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2024-200701

Published: 2024

Journal Articles

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla

Blood (2024) 144 (10): 1061–1068.

https://doi.org/10.1182/blood.2023023659

Published: 2024

Includes: Supplemental data

Journal Articles

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Blood (2023) 142 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2023-173092

Published: 2023

Journal Articles

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2023) 142 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2023-186517

Published: 2023

Journal Articles

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Liliya Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

Blood (2023) 142 (Supplement 1): 4563.

https://doi.org/10.1182/blood-2023-173499

Published: 2023

Journal Articles

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger

Blood (2022) 140 (Supplement 1): 9663–9664.

https://doi.org/10.1182/blood-2022-156889

Published: 2022

Journal Articles

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 6558–6560.

https://doi.org/10.1182/blood-2022-167644

Published: 2022

Journal Articles

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Blood (2022) 140 (Supplement 1): 10434–10436.

https://doi.org/10.1182/blood-2022-169736

Published: 2022

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Blood (2021) 138 (Supplement 1): 2344.

https://doi.org/10.1182/blood-2021-147769

Published: 2021

Journal Articles

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Wojciech Jurczak, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Šimkovič, Iryna Kriachok, Arpad Illes, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Min Hui Wang, Ting Yu, Paolo Ghia

Blood (2021) 138 (Supplement 1): 393.

https://doi.org/10.1182/blood-2021-146570

Published: 2021

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

Evaluation of PET/CT during upfront therapy as a prognosticator in follicular lymphoma patients at the University of Debrecen

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only